BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:NVL-330 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of NVL-330\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06521554-2646@assetmemo.bio
DTSTAMP:20261121T005708Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:NVL-330: Phase 1 readout est. (NCT06521554)
DESCRIPTION:NVL-330\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A Study
  of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HE
 ROEX-1)\nEstimated primary completion: January 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/nvl-330#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06521554
URL:https://assetmemo.bio/drug/nvl-330#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
